Piroxicam | CP-16171 | COX Inhibitor | AmBeed-信号通路专用抑制剂

首页 / / / / Piroxicam

吡罗昔康 /Piroxicam {[allProObj[0].p_purity_real_show]}

货号：A265438 同义名： CP-16171;NSC 666076

Piroxicam is a selective COX1 inhibitor with anti-inflammatory effects.

HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type	HazMat fee for 500 gram (Estimated)
Excepted Quantity	USD 0.00
Limited Quantity	USD 15-60
Inaccessible (Haz class 6.1), Domestic	USD 80+
Inaccessible (Haz class 6.1), International	USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic	USD 100+
Accessible (Haz class 3, 4, 5 or 8), International	USD 200+

Piroxicam 化学结构
CAS号：36322-90-4

Piroxicam 3D分子结构
CAS号：36322-90-4

规格	价格	会员价	库存	数量
{[ item.pr_size ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]}	{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]}	现货	咨询	- +

购物车0 收藏询单

sales@ambeed.cn tech@ambeed.cn 400-920-2911 产品手册产品订购技术咨询
快速发货顺丰冷链运输，1-2 天到达

品质保证

技术支持

免费溶解

Piroxicam 纯度/质量文件产品仅供科研

货号：A265438 标准纯度： {[allProObj[0].p_purity_real_show]} 产品说明书

批次查询：批次纯度: COA SDS NMR HPLC CNMR LC-MS

全球学术期刊中引用的产品: • Nat. Biomed. Eng., 2024, 8, 1412-1424. Ambeed. [ A538667 , A631746 ]; • JMC, 2024. Ambeed. [ A833302 , A475501 , A341986 , A356070 ]; • BMC Cancer, 2024, 24(1): 1415. Ambeed. [ A809692 , A209020 ]; • J. Am. Soc. Mass Spectrom., 2024, 35(12): 3192-3202. Ambeed. [ A166127 , A902473 , A753371 , A961334 , A292945 , A230770 , A300620 , A1114580 , A1159765 , A206238 ]; • PloS One, 2024, 19(11): e0308060. Ambeed. [ A302917 ]; 更多 >

环氧化酶亚型比较

产品名称	COX ↓ ↑	COX-1 ↓ ↑	COX-2 ↓ ↑	纯度
Piroxicam	✔			98%
Salicylic acid	✔			98%
Phenacetin	✔			98%
Etodolac	✔			99%
Flunixin meglumine	✔			98%
Ibuprofen L-lysine	✔			99%
Nabumetone	✔			98%
Acemetacin	✔			98%
Diflunisal	✔			98%
Pranoprofen	✔			98%
Ampiroxicam	✔			98%
Meloxicam	✔			98%
Sulindac	✔			98%
Ketoprofen		✔		98%
Mefenamic Acid		✔		95%
Bromfenac sodium		✔		98%
Oxaprozin		✔		99%
Aspirin		✔		99%
Nepafenac		✔		98%
Zaltoprofen		✔		99%
Salicin		✔		98%
Suprofen		✔		99%+
Xanthohumol		✔		99%
Parecoxib			✔	98%
Tolfenamic Acid			+++ COX-2, IC50: 0.2 μM	98%
Etoricoxib			✔	99%
Niflumic Acid			✔	98%
Valdecoxib			++++ COX-2, IC50: 5 nM	99+%
Ibuprofen		+ COX-1, IC50: 13 μM	+ COX-2, IC50: 370 μM	98%
Indomethacin		++ COX1, IC50: 0.28 μM	+ COX-2, IC50: 14 μM	97%
Lornoxicam		++++ COX-1, IC50: 5 nM	++++ COX-2, IC50: 8 nM	98%
Meclofenamic acid sodium		++++ COX-1, IC50: 40 nM	+++ COX-2, IC50: 50 nM	99%
Rofecoxib			++++ COX-2, IC50: 18 nM	98%
Asaraldehyde			✔	98%
Naproxen		+ COX-1, IC50: 8.7 μM	+ COX-2, IC50: 5.2 μM	98%
Diclofenac Sodium Salt		+++ COX-1, IC50: 60 nM	+++ COX-2, IC50: 200 nM	98%
NS-398			++ COX-2, IC50: 3.8 μM	98%
Amfenac Sodium Hydrate		++ COX-1, IC50: 250 nM	+++ COX-2, IC50: 150 nM	98%+
Nimesulide			+ COX-2, IC50: 26 μM	98%
Lumiracoxib		++ COX-1, Ki: 3 μM	+++ COX-2, Ki: 60 nM	98%
Rutaecarpine			✔	95%
Celecoxib			++++ COX-2, IC50: 40 nM	98%
Carprofen			++++ canine COX2, IC50: 30 nM	98%
Ketorolac		++ COX-1 (human), IC50: 1.23 μM	++ COX-2 (human), IC50: 3.50 μM	98%
1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多，抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用，但抑制强度暂时没有相关数据。

Piroxicam 生物活性

靶点

描述

Piroxicam is a non-steroidal anti-inflammatory drugs, acts as a COX inhibitor, with IC50s of 47, 25 μM for human monocyte COX-1 and COX-2, respectively^[3]. Piroxicam (0.3 mg/kg qd 24-h p.o.) reduces tumor volume in 12 of 18 dogs, and such and effect is via induction of apoptosis and reduction in urine basic fibroblast growth factor concentration^[4]. Piroxicam (167, 333, 500 μM) decreases cell population of T24 and the 5637 cells. Piroxicam (500 μM) also reduces the cell viability of T24 and 5637 cell, and is significantly effective when combined with 0.05 μM carboplatin. The combination also inhibits Ki-67 expression in booth cells. In vitro combination of carboplatin and piroxicam produced a more potent antiproliferative effect when compared to single drugs^[5].

Piroxicam 临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT03038321	Non-Muscle-invasive Bladder Ca... 展开 >>ncer (NMIBC) Bacillus Calmette-Guerin (BCG) Cystitis Intra-vesical Instillation 收起 <<	Phase 4	Active, not recruiting	December 2019	Egypt ... 展开 >> Urology and Nephrology Center Mansoura, Aldakahlia, Egypt, 35516 收起 <<
NCT02457325	Impacted Third Molar Tooth ... 展开 >> Adverse Reaction to Other Local Anesthetics 收起 <<	Phase 4	Completed	-	-
NCT02160236	Postoperative Pain	Phase 4	Unknown	February 2015	Turkey ... 展开 >> Erciyes Universty Hospital Recruiting Kayseri, Turkey, 38039 Contact: nazife küçük, resident +905072317446 nzfkucuk@hotmail.com 收起 <<

Piroxicam 参考文献

[1]Vartiainen N, Huang CY, et al. Piroxicam and NS-398 rescue neurones from hypoxia/reoxygenation damage by a mechanism independent of cyclo-oxygenase inhibition. J Neurochem. 2001 Jan;76(2):480-9.

[2]Rigas B, Tsioulias GJ, et al. The effect of bile acids and piroxicam on MHC antigen expression in rat colonocytes during colon cancer development. Immunology. 1994 Oct;83(2):319-23.

[3]Kato M, Nishida S, Kitasato H, Sakata N, Kawai S. Cyclooxygenase-1 and cyclooxygenase-2 selectivity of non-steroidal anti-inflammatory drugs: investigation using human peripheral monocytes. J Pharm Pharmacol. 2001;53(12):1679-1685

[4]Mohammed SI, Bennett PF, Craig BA, et al. Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Res. 2002;62(2):356-358

[5]Silva J, Arantes-Rodrigues R, Pinto-Leite R, et al. Synergistic Effect of Carboplatin and Piroxicam on Two Bladder Cancer Cell Lines. Anticancer Res. 2017;37(4):1737-1745

Piroxicam 实验方案

计算器

存储液制备

1mg

5mg

10mg

1 mM

5 mM

10 mM

3.02mL

0.60mL

0.30mL

15.09mL

3.02mL

1.51mL

30.18mL

6.04mL

3.02mL

Piroxicam 技术信息

CAS号	36322-90-4
分子式	C₁₅H₁₃N₃O₄S
分子量	331.346

别名	CP-16171;NSC 666076
运输	蓝冰

存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Sealed in dry,2-8°C

溶解度

DMSO: 50 mg/mL(150.9 mM)，配合低频超声助溶，注意：DMSO长时间开封后，会吸水并导致溶解能力下降，请避免使用长期开封的DMSO

动物实验配方

临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT03038321	Non-Muscle-invasive Bladder Ca... 展开 >>ncer (NMIBC) Bacillus Calmette-Guerin (BCG) Cystitis Intra-vesical Instillation 收起 <<	Phase 4	Active, not recruiting	December 2019	Egypt ... 展开 >> Urology and Nephrology Center Mansoura, Aldakahlia, Egypt, 35516 收起 <<
NCT02457325	Impacted Third Molar Tooth ... 展开 >> Adverse Reaction to Other Local Anesthetics 收起 <<	Phase 4	Completed	-	-
NCT02160236	Postoperative Pain	Phase 4	Unknown	February 2015	Turkey ... 展开 >> Erciyes Universty Hospital Recruiting Kayseri, Turkey, 38039 Contact: nazife küçük, resident +905072317446 nzfkucuk@hotmail.com 收起 <<
NCT02191358	-		Completed	-	United States, California ... 展开 >> Dr. Michael Dao Garden Grove, California, United States, 92844 United States, Colorado Kaiser Permanente Colorado Denver, Colorado, United States, 80011 United States, Kentucky Gill Heart Institute Lexington, Kentucky, United States, 40508 United States, Maryland IRC Clinics Towson, Maryland, United States, 21204 United States, Massachusetts Internal Medicine & Cardiology Associates Fall River, Massachusetts, United States, 02720 Prima CARE Fall River, Massachusetts, United States, 02720 United States, Virginia Carilion Clinic Christiansburg, Virginia, United States, 24073 收起 <<
NCT00293631	Bunionectomy ... 展开 >>Orthopedic Surgery 收起 <<	Phase 2	Completed	-	United States, California ... 展开 >> Advanced Clinical Research Institute Anaheim, California, United States, 92801 收起 <<
NCT01718756	Closed Non Comminuted Long Bon... 展开 >>e Fractures 收起 <<	Phase 1 Phase 2	Unknown	February 2016	Egypt ... 展开 >> Anesthesiology Dept., College of Medicine, Mansoura University Recruiting Mansoura, DK, Egypt, 050 Sub-Investigator: Salwa Hawas, MD Principal Investigator: Eiad A Ramzy, MD Sub-Investigator: Douaa G Diab, MD Sub-Investigator: Nahla S El Bahnsawy, MD Sub-Investigator: Hany A Mowafi, MD Sub-Investigator: Talal A Albrahimi, MD 收起 <<
NCT02025166	Pain	Not Applicable	Unknown	January 2015	Israel ... 展开 >> Rambam Health Care Campus Not yet recruiting Haifa, Israel Contact: Lior Lowenstein, MD, MS 972502061434 l_lior@rambam.health.gov.il Principal Investigator: Susana Mustafa, MD 收起 <<
NCT01055470	Osteoarthritis of Knee Joint	Not Applicable	Completed	-	India ... 展开 >> Sir Takthasinhji General Hospital Bhavnagar, Gujarat, India, 364001 收起 <<
NCT02549118	Analgesia Obs... 展开 >>tetrical 收起 <<	Phase 2	Unknown	March 2016	-
NCT01069055	Inguinal Hernia ... 展开 >> Postoperative Pain 收起 <<	Phase 3	Unknown	June 2010	Turkey ... 展开 >> Diskapi Teaching and Research Hospital Not yet recruiting Ankara, Turkey Contact: Alp Alptekin, MD +90 312 5962370 alptekinmd@yahoo.com Contact: Hakan Kulacoglu, MD, FACS hakankulacoglu@hotmail.com 收起 <<
NCT02750917	Postoperative Pain	Phase 3	Completed	-	-
NCT01564680	Postoperative Pain	Phase 4	Completed	-	Saudi Arabia ... 展开 >> Dammam University, KFHU Al-Khobar, EP, Saudi Arabia, 31952 收起 <<
NCT00997750	Acute Coronary Syndrome	Phase 4	Completed	-	Russian Federation ... 展开 >> Central Clinical Hospital of Presidential Department Of Russian Federation Moscow, Russian Federation 收起 <<
NCT00530387	Dermatitis, Photocontact	Not Applicable	Completed	-	United Kingdom ... 展开 >> Photobiology Unit, Ninewells Hospital, Dundee, Angus, United Kingdom, DD1 9SY 收起 <<
NCT01480752	Post Operative Endodontic Pain	Phase 2	Completed	-	Iran, Islamic Republic of ... 展开 >> Dental School of Azad University Tehran, Iran, Islamic Republic of, 1946853314 收起 <<
NCT01117948	-		Terminated(Lack of Efficacy)	-	-
NCT00293657	Headache (Migraine)	Phase 2	Completed	-	-
NCT03092193	Poor Metabolizer Due to Cytoch... 展开 >>rome P450 CYP2C9 Variant Poor Metabolizer Due to Cytochrome p450 CYP2C19 Variant 收起 <<	Phase 4	Recruiting	December 2018	Brazil ... 展开 >> Bauru School of Dentistry/USP Recruiting Bauru, São Paulo, Brazil, 17012-901 Contact: Adriana M Calvo, PhD 551432358276 birinjela@yahoo.com.br 收起 <<
NCT01117948	Alzheimer´s Disease	Phase 2	Terminated(Lack of Efficacy)	-	-
NCT02382653	Neoplasm Metastases	Not Applicable	Completed	-	-
NCT00649415	Dysmenorrhea	Phase 4	Completed	-	Brazil ... 展开 >> Pfizer Investigational Site Salvador, Bahia, Brazil Pfizer Investigational Site Goiania, Goias, Brazil Pfizer Investigational Site Belo Horizonte, Minas Gerais, Brazil, 30130-100 Pfizer Investigational Site Belo Horizonte, Minas Gerais, Brazil, 30130-110 Pfizer Investigational Site Porto Alegre, Rio Grande Do Sul, Brazil, 90610-000 Pfizer Investigational Site Rio De Janeiro, RJ, Brazil, 20551-030 Pfizer Investigational Site Porto Alegre, RS, Brazil Pfizer Investigational Site São Paulo, SP, Brazil Pfizer Investigational Site Sao Paulo, Brazil Pfizer Investigational Site São Paulo, Brazil, 04062-003 收起 <<
NCT00631514	Hypertension	Phase 4	Completed	-	Croatia ... 展开 >> Split University School of Medicine. Family Practice Department Split, Croatia, 21000 收起 <<
NCT02285972	Injection Pain	Phase 4	Completed	-	Turkey ... 展开 >> Anesthesiology and Reanimation Dept. Ordu University Training and Research Hospital Altınordu, Ordu, Turkey, 52100 收起 <<
NCT02304783	Renal Colic	Phase 1 Phase 2	Unknown	March 2018	Tunisia ... 展开 >> Emergency Department of University Hospital of Monastir Recruiting Monastir, Tunisia, 5050 Contact: bzeouich nasri, Resident 52919170 ext 00216 medecinasri@gmail.com Principal Investigator: Nouira Samir, Professor 收起 <<
NCT00670475	Osteoarthritis of the Knee	Phase 2	Completed	-	Iran, Islamic Republic of ... 展开 >> ArdabiUMS clinic of rheumatology Ardabil, Iran, Islamic Republic of, 56197 收起 <<
NCT03745105	Postoperative Pain	Not Applicable	Not yet recruiting	December 1, 2019	-
NCT03626753	Cesarean Section; Complication... 展开 >>s, Wound, Infection (Following Delivery) Postoperative Pain Spinal Anaesthesia During the Puerperium 收起 <<	Phase 2 Phase 3	Completed	-	Tunisia ... 展开 >> Centre de Maternité de Monastir Monastir, Tunisia, 5000 收起 <<
NCT01320709	Contraception, Postcoital	Phase 2	Completed	-	Germany ... 展开 >> Berlin, Germany, 13353 收起 <<
NCT03614494	Emergency Contraception	Phase 2 Phase 3	Recruiting	October 30, 2020	Hong Kong ... 展开 >> Queen Mary Hospital Active, not recruiting Hong Kong, Hong Kong The Family Planning Association of Hong Kong Recruiting Hong Kong, Hong Kong Contact: Sue Lo, MD, FRCOG 29197726 stlo@famplan.org.hk 收起 <<
NCT03006107	Pulpitis - Irreversible	Not Applicable	Unknown	January 2018	-
NCT02450487	Pain Other Su... 展开 >>rgical Procedures Impacted Third Molar Tooth Cytochrome P450 CYP2C9 Enzyme Deficiency 收起 <<	Phase 4	Completed	-	-
NCT03612323	Pulpitis - Irreversible	Early Phase 1	Not yet recruiting	August 2019	-
NCT03153657	Tooth Sensitivity ... 展开 >> Toothache 收起 <<	Phase 3	Completed	-	Brazil ... 展开 >> Hospital Universitário - Universidade Federal de Sergipe Aracaju, Sergipe, Brazil, 490000 收起 <<
NCT02253446	Primary Dysmenorrhea	Phase 4	Completed	-	Turkey ... 展开 >> Pamukkale Universty Denizli, Turkey, 20000 收起 <<

吡罗昔康 /Piroxicam {[allProObj[0].p_purity_real_show]}

Piroxicam 纯度/质量文件产品仅供科研

全球学术期刊中引用的产品

Piroxicam 质控信息

Piroxicam 生物活性

Piroxicam 临床研究

Piroxicam 参考文献

Piroxicam 实验方案

Piroxicam 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

吡罗昔康 /Piroxicam {[allProObj[0].p_purity_real_show]}

Piroxicam 纯度/质量文件 产品仅供科研

全球学术期刊中引用的产品

Piroxicam 质控信息

Piroxicam 生物活性

Piroxicam 临床研究

Piroxicam 参考文献

Piroxicam 实验方案

Piroxicam 技术信息

最近浏览的产品

大规格询价

摩尔计算器

靶点

总药量计算器

工作液计算器

细胞研究

临床研究

确认信息

请登录您的专属账户

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

Piroxicam 纯度/质量文件产品仅供科研